Join the Breast Cancer, Metastatic group to help and get support from people like you.
Breast Cancer, Metastatic News (Page 5)
Related terms: Metastatic Breast Cancer
Ibrance (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer
March 31, 2017 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its first-in-class cyclin...
FDA Approves Kisqali (ribociclib) for HR+/HER2- Metastatic Breast Cancer
Basel, March 13, 2017 - The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based...
Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR+, HER2- Metastatic Breast Cancer
Friday, February 19, 2016 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of Ibrance (palbociclib) 125mg...
FDA Approves Ibrance (palbociclib) for Postmenopausal Women with Advanced Breast Cancer
February 3, 2015 – The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer. Breast cancer in women is the...
FDA Approves Lymphoseek to Help Locate Lymph Nodes in Patients with Certain Cancers
March 13, 2013 – The U.S. Food and Drug Administration today approved Lymphoseek (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph...
FDA Approves Kadcyla for Late-Stage Breast Cancer
February 22, 2013 – The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. ...
FDA Approves Perjeta (pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
South San Francisco, Calif. – June 8, 2012 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Perjeta (pertuzumab). Perjeta is...
FDA Approves Halaven for Late-Stage Breast Cancer
SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have...
FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 20, 2010 - Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab)...
FDA Approves New Dosing for Faslodex (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of Faslodex (fulvestrant) Injection,...
GSK's Tykerb Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
PHILADELPHIA, Jan. 29 /PRNewswire/ – GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using Tykerb...
Further information
Related condition support groups
Related drug support groups
anastrozole, letrozole, Arimidex, Herceptin, Femara, tamoxifen, trastuzumab, Ibrance